Skip to content

Humana HUM Additional Paid-In Capital

Additional Paid-In Capital at other companies

UnitedHealth Group logo
UnitedHealth GroupUNH
$556M
Centene logo
CenteneCNC
$20.82B+0.9%
Elevance Health logo
Elevance HealthELV
$8.85B-0.2%
Molina Healthcare logo
Molina HealthcareMOH
$471M+8.5%
Clover Health Investments logo
Clover Health InvestmentsCLOV
$2.7B+3.5%
Alignment Healthcare logo
Alignment HealthcareALHC
$1.2B+7.0%

Other financials

Income statement

See full
Revenue$39.6B+23.5%
Operating income$1.8B-12.9%
Net income$1.2B-4.7%
EPS (diluted)$9.83-4.6%

Balance sheet

See full
Cash & equivalents$5.0B+16.5%
Total debt$14.0B+5.2%
Total equity$18.6B+4.7%
Total assets$55.3B+8.5%

Cash flow

See full
Operating cash flow$1.3B+279%
CapEx$121.0M+27.4%
Free cash flow$1.1B+380%

Valuation

See full
Market cap$47.69B+64.5%
Enterprise value$56.73B+51.1%
P/E15×-1.9×
P/S0.4×+0.1×

Profitability

See full
Operating margin2.7%-1.7pp
Net margin3%-0.1pp
FCF margin4.2%

Returns & leverage

See full
Return on equity18.2%+0.9pp
Debt / equity0.8×0.0×
Current ratio1.8×-0.1×

Where this comes from

Reported directly by Humana in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Humana’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Humana's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Humana's additional paid-in capital?
Humana (HUM) reported additional paid-in capital of $3.64B in Q1 2026.
How has Humana's additional paid-in capital changed year-over-year?
Humana's additional paid-in capital increased by 4.1% year-over-year, from $3.5B to $3.64B.
What is the long-term trend for Humana's additional paid-in capital?
Over 5 years (2020 to 2025), Humana's additional paid-in capital has grown at a 5.9% compound annual growth rate (CAGR), from $2.71B to $3.6B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.